Company intelligence / Profile preview
ViroMed Co., Ltd.
Seoul, Seoul, South Koreaviromed.co.kr ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 3
01
Overview
ViroMed has advanced its lead candidate, VM202, a gene therapy delivering the HGF gene via intramuscular injection, into late-stage clinical trials for diabetic peripheral neuropathy and other indications. The company has a total of eight projects in clinical stages across the US, Korea, and China. Early results have shown promise in treating chronic and incurable diseases such as diabetic foot ulcers and ALS.
- Therapeutic areas
- OncologyEndocrinologyCardiovascularNeurology
- Modalities
- Gene therapyNovel biologicsBotanical therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Reyon Pharm. (Korea)PMG Pharm. (Korea)Beijing Northland Biotech (China)Yuhan Corporation
Beyond the preview
Go deeper on ViroMed Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViroMed Co., Ltd..